These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 2811008)

  • 41. The Mycobacterium tuberculosis iniA gene is essential for activity of an efflux pump that confers drug tolerance to both isoniazid and ethambutol.
    Colangeli R; Helb D; Sridharan S; Sun J; Varma-Basil M; Hazbón MH; Harbacheuski R; Megjugorac NJ; Jacobs WR; Holzenburg A; Sacchettini JC; Alland D
    Mol Microbiol; 2005 Mar; 55(6):1829-40. PubMed ID: 15752203
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The relationship between the in vitro drug susceptibility of opportunist mycobacteria and their in vivo response to treatment.
    Heginbothom ML
    Int J Tuberc Lung Dis; 2001 Jun; 5(6):539-45. PubMed ID: 11409581
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Lung diseases caused by non-tuberculous mycobacteria in East Germany and Hungary].
    Kalich R; Käppler W; Fischer P; Vandra E; Kozma D
    Pneumologie; 1989 Mar; 43(3):169-72. PubMed ID: 2785269
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [In vitro antimicrobial activity of a new quinolone, levofloxacin, against atypical mycobacteria].
    Oya S; Takemoto A; Hosaka K; Kudou Y; Arakawa M
    Kekkaku; 1995 Nov; 70(11):615-9. PubMed ID: 8656585
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Spectrum of activity of levofloxacin against nontuberculous mycobacteria and its activity against the Mycobacterium avium complex in combination with ethambutol, rifampin, roxithromycin, amikacin, and clofazimine.
    Rastogi N; Goh KS; Bryskier A; Devallois A
    Antimicrob Agents Chemother; 1996 Nov; 40(11):2483-7. PubMed ID: 8913450
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Nontuberculous mycobacteriosis; the present status and in the future. 3--(1). The view of development of new drugs against nontuberculous mycobacterial infections].
    Kawahara S; Nagare H
    Kekkaku; 1998 Feb; 73(2):77-82. PubMed ID: 9545700
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Minimal inhibitory concentrations of isoniazid, rifampin, ethambutol, and streptomycin against Mycobacterium tuberculosis strains isolated before treatment of patients in Taiwan.
    Suo J; Chang CE; Lin TP; Heifets LB
    Am Rev Respir Dis; 1988 Oct; 138(4):999-1001. PubMed ID: 3144210
    [TBL] [Abstract][Full Text] [Related]  

  • 48. First randomised trial of treatments for pulmonary disease caused by M avium intracellulare, M malmoense, and M xenopi in HIV negative patients: rifampicin, ethambutol and isoniazid versus rifampicin and ethambutol.
    Research Committee of the British Thoracic Society
    Thorax; 2001 Mar; 56(3):167-72. PubMed ID: 11182006
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [A case of pulmonary infection caused by Mycobacterium szulgai].
    Haranaga S; Sato Y; Tohyama M; Toyama M; Ishimine T; Miyara T; Shinzato T; Higa F; Tateyama M; Saito A
    Kekkaku; 2002 May; 77(5):421-5. PubMed ID: 12073620
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Bacteriology of mycobacteria: taxonomic and morphological characteristics].
    Tomioka H
    Nihon Rinsho; 1998 Dec; 56(12):3001-7. PubMed ID: 9883600
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Antimycobacterial drugs.
    Heifets LB
    Semin Respir Infect; 1994 Jun; 9(2):84-103. PubMed ID: 7973175
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Nontuberculous mycobacteriosis].
    Nagai H
    Nihon Rinsho; 2003 Feb; 61 Suppl 2():523-30. PubMed ID: 12722274
    [No Abstract]   [Full Text] [Related]  

  • 53. Numerical classification of 280 strains of slowly growing mycobacteria. Proposal of Mycobacterium tuberculosis series, Mycobacterium avium series, and Mycobacterium nonchromogenicum series.
    Tsukamura M
    Microbiol Immunol; 1983; 27(4):315-34. PubMed ID: 6412041
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Activities of clarithromycin against eight slowly growing species of nontuberculous mycobacteria, determined by using a broth microdilution MIC system.
    Brown BA; Wallace RJ; Onyi GO
    Antimicrob Agents Chemother; 1992 Sep; 36(9):1987-90. PubMed ID: 1416891
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Comparative in vitro activities of linezolid, telithromycin, clarithromycin, levofloxacin, moxifloxacin, and four conventional antimycobacterial drugs against Mycobacterium kansasii.
    Alcaide F; Calatayud L; Santín M; Martín R
    Antimicrob Agents Chemother; 2004 Dec; 48(12):4562-5. PubMed ID: 15561826
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Pulmonary infection due to Mycobacterium szulgai, a group 2 nontuberculous mycobacterium].
    Nyui M; Katura T; Tanaka K; Yoshida H
    Nihon Kokyuki Gakkai Zasshi; 2001 Dec; 39(12):920-3. PubMed ID: 11875808
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Pulmonary disease due to Mycobacterium xenopi. Report of two cases.
    Bogaerts Y; Elinck W; van Renterghem D; Pauwels R; van der Straeten M
    Eur J Respir Dis; 1982 Jul; 63(4):298-304. PubMed ID: 7117427
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Rapid mycobacteria drug susceptibility testing using Gel Microdrop (GMD) Growth Assay and flow cytometry.
    Akselband Y; Cabral C; Shapiro DS; McGrath P
    J Microbiol Methods; 2005 Aug; 62(2):181-97. PubMed ID: 16009276
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Sensitivity of opportunist mycobacteria to rifampicin and ethambutol.
    Yates MD; Collins CH
    Tubercle; 1981 Jun; 62(2):117-21. PubMed ID: 7303160
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Nontuberculous mycobacteria isolated from pulmonary specimens between 2004 and 2009: causative agent or not?
    Bicmen C; Coskun M; Gunduz AT; Senol G; Cirak AK; Tibet G
    New Microbiol; 2010 Oct; 33(4):399-403. PubMed ID: 21213600
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.